☆ 4.6 Meeting Abstract

Dual ALK Fusion Partners as Poor Predictive Marker in First Line Crizotinib Treated ALK Rearranged Non-Small Cell Lung Cancer

JOURNAL OF THORACIC ONCOLOGY (2019)

Journal

JOURNAL OF THORACIC ONCOLOGY

Volume 14, Issue 10, Pages S849-S850

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.jtho.2019.08.1836

Keywords

Next Generation Sequencing; ALK; Fusion partners; crizotinib

Categories

Oncology Respiratory System

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.